Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naïve patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from...

por Emery, P, Bingham, C O, Burmester, G R, Bykerk, V P, Furst, D E, Mariette, X, van der Heijde, D, van Vollenhoven, R, Arendt, C, Mountian, I, Purcaru, O, Tatla, D, VanLunen, B, Weinblatt, M E
Publicado 2017